PRO DEX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PRO DEX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $66.59M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $53.84M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $46.09M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | $42.04M | Oct 13, 2023 |
| FY2023 | Jun 30, 2021 | $38.03M | Oct 13, 2023 |
| FY2021 | Jun 30, 2020 | $34.83M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $27.17M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $22.47M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | $21.94M | Sep 13, 2018 |
| FY2016 | Jun 30, 2016 | $20.16M | Sep 15, 2016 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $21.94M | Sep 14, 2017 |
| FY2017 | Jun 30, 2016 | $19.19M | Sep 14, 2017 |
| FY2016 | Jun 30, 2015 | $13.38M | Sep 15, 2016 |
| FY2015 | Jun 30, 2014 | $10.81M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $12.25M | Sep 18, 2014 |
| FY2013 | Jun 30, 2012 | $17.26M | Sep 27, 2013 |
| FY2012 | Jun 30, 2011 | $24.06M | Sep 12, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.51M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $14.55M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $12.75M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | $13.13M | Oct 13, 2023 |
| FY2023 | Jun 30, 2021 | $13.58M | Oct 13, 2023 |
| FY2021 | Jun 30, 2020 | $13.14M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $9.78M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $7.94M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | $7.19M | Sep 13, 2018 |
| FY2017 | Jun 30, 2016 | $4.92M | Sep 14, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.98M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $2.13M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $7.07M | Sep 5, 2024 |
| FY2023 | Mar 31, 2023 | $1.62M | Oct 13, 2023 |
| FY2023 | Dec 31, 2022 | $2.75M | Oct 13, 2023 |
| FY2023 | Sep 30, 2022 | $1.20M | Oct 13, 2023 |
| FY2023 | Jun 30, 2022 | $1.84M | Oct 13, 2023 |
| FY2023 | Mar 31, 2022 | $574.0K | Oct 13, 2023 |
| FY2023 | Dec 31, 2021 | $1.08M | Oct 13, 2023 |
| FY2023 | Sep 30, 2021 | $1.08M | Oct 13, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $10.69M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $7.17M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $5.76M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | $5.12M | Oct 13, 2023 |
| FY2023 | Jun 30, 2021 | $4.53M | Oct 13, 2023 |
| FY2021 | Jun 30, 2020 | $7.07M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $5.00M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $2.39M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | $2.74M | Sep 13, 2018 |
| FY2017 | Jun 30, 2016 | $807.0K | Sep 14, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.64M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $3.19M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $2.80M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | $2.98M | Oct 13, 2023 |
| FY2023 | Jun 30, 2021 | $4.38M | Oct 13, 2023 |
| FY2021 | Jun 30, 2020 | $2.32M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $1.88M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $1.89M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | $1.23M | Sep 13, 2018 |
| FY2017 | Jun 30, 2016 | $1.20M | Sep 14, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.68M) | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $6.22M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $5.46M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | ($847.0K) | Oct 13, 2023 |
| FY2023 | Jun 30, 2021 | ($2.08M) | Oct 13, 2023 |
| FY2021 | Jun 30, 2020 | $4.95M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $3.33M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $3.10M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | $3.24M | Sep 13, 2018 |
| FY2017 | Jun 30, 2016 | $466.0K | Sep 14, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | $1.64M | Sep 8, 2022 |
| FY2022 | Jun 30, 2021 | $1.77M | Sep 8, 2022 |
| FY2021 | Nov 6, 2020 | $6.50M | Sep 9, 2021 |
| FY2021 | Jun 30, 2020 | $519.0K | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $1.39M | Sep 10, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $61.19M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $52.48M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $51.82M | Sep 5, 2024 |
| FY2023 | Mar 31, 2023 | $51.69M | Oct 13, 2023 |
| FY2023 | Dec 31, 2022 | $51.88M | Oct 13, 2023 |
| FY2023 | Sep 30, 2022 | $49.86M | Oct 13, 2023 |
| FY2023 | Jun 30, 2022 | $49.09M | Oct 13, 2023 |
| FY2023 | Mar 31, 2022 | $45.22M | Oct 13, 2023 |
| FY2023 | Dec 31, 2021 | $43.33M | Oct 13, 2023 |
| FY2023 | Sep 30, 2021 | $42.93M | Oct 13, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $24.56M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $21.61M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $20.23M | Sep 5, 2024 |
| FY2023 | Mar 31, 2023 | $21.79M | Oct 13, 2023 |
| FY2023 | Dec 31, 2022 | $23.64M | Oct 13, 2023 |
| FY2023 | Jun 30, 2022 | $23.66M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $20.24M | Sep 8, 2022 |
| FY2021 | Jun 30, 2020 | $12.06M | Sep 9, 2021 |
| FY2021 | Jul 2, 2019 | $3.30M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | $8.51M | Sep 10, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $36.63M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $30.87M | Sep 4, 2025 |
| FY2025 | Jun 30, 2023 | $31.59M | Sep 4, 2025 |
| FY2024 | Jun 30, 2022 | $25.43M | Sep 5, 2024 |
| FY2023 | Jun 30, 2021 | $21.13M | Oct 13, 2023 |
| FY2023 | Jun 30, 2020 | $19.06M | Oct 13, 2023 |
| FY2021 | Jun 30, 2019 | $17.01M | Sep 9, 2021 |
| FY2020 | Jun 30, 2018 | $17.28M | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $13.71M | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | $8.88M | Sep 13, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $112.0K | Sep 14, 2017 |
| FY2017 | Jun 30, 2016 | $112.0K | Sep 14, 2017 |
| FY2018 | Jun 30, 2015 | $353.0K | Sep 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $35.93M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $26.95M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $24.82M | Sep 5, 2024 |
| FY2023 | Mar 31, 2023 | $23.32M | Oct 13, 2023 |
| FY2023 | Dec 31, 2022 | $21.70M | Oct 13, 2023 |
| FY2023 | Sep 30, 2022 | $18.95M | Oct 13, 2023 |
| FY2023 | Jun 30, 2022 | $17.75M | Oct 13, 2023 |
| FY2023 | Mar 31, 2022 | $15.91M | Oct 13, 2023 |
| FY2023 | Dec 31, 2021 | $15.34M | Oct 13, 2023 |
| FY2023 | Sep 30, 2021 | $14.26M | Oct 13, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $419.0K | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $2.63M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $2.94M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | $849.0K | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $3.72M | Sep 8, 2022 |
| FY2022 | Jun 30, 2020 | $6.42M | Sep 8, 2022 |
| FY2021 | Jun 30, 2019 | $7.74M | Sep 9, 2021 |
| FY2020 | Jun 30, 2018 | $5.19M | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $4.21M | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | $2.29M | Sep 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $15.43M | Sep 4, 2025 |
| FY2024 | Jun 30, 2024 | $11.96M | Sep 5, 2024 |
| FY2023 | Jun 30, 2023 | $12.80M | Oct 13, 2023 |
| FY2022 | Jun 30, 2022 | $13.59M | Sep 8, 2022 |
| FY2021 | Jun 30, 2021 | $12.84M | Sep 9, 2021 |
| FY2020 | Jun 30, 2020 | $3.98M | Sep 10, 2020 |
| FY2019 | Jun 30, 2019 | $4.60M | Sep 12, 2019 |
| FY2012 | Jun 30, 2012 | $393.0K | Sep 12, 2012 |
| FY2012 | Jun 30, 2011 | $1.22M | Sep 12, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 2 | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | 1 | Sep 5, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Oct 13, 2023 |
| FY2023 | Dec 31, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Sep 30, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Jun 30, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Mar 31, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Dec 31, 2021 | 0 | Oct 13, 2023 |
| FY2023 | Sep 30, 2021 | 0 | Oct 13, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 2 | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | 1 | Sep 5, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Oct 13, 2023 |
| FY2023 | Dec 31, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Sep 30, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Jun 30, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Mar 31, 2022 | 0 | Oct 13, 2023 |
| FY2023 | Dec 31, 2021 | 0 | Oct 13, 2023 |
| FY2023 | Sep 30, 2021 | 0 | Oct 13, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 3.26M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | 3.36M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | 3.55M | Sep 5, 2024 |
| FY2023 | Jun 30, 2022 | 3.60M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 3.65M | Sep 8, 2022 |
| FY2021 | Jun 30, 2020 | 3.81M | Sep 9, 2021 |
| FY2020 | Jun 30, 2019 | 4.04M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | 4.33M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | 4.03M | Sep 13, 2018 |
| FY2017 | Jun 30, 2016 | 4.05M | Sep 14, 2017 |